Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Induction Chemo-Nivo in Unresectable Stage III NSCLC

A legfontosabb adatok

Ki végzi
Ralph G Zinner
Hol
Lexington (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
1 fő vett részt
Kezdés
2023. dec. 13.
Befejezés
2024. júl. 5.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Nivolumab and Chemotherapy
  • Nivolumab
  • Post Induction Surgery
  • Post Induction XRT
A regiszteradat frissítve
2025. április 30.
Miért állt le
Slow accrual

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated
  • PD-L1 level needs to be measured with values 0-100% eligible
  • EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes
  • ECOG Performance Status ≤ 1
  • Adequate organ and marrow function
  • Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better
  • Ability to understand and the willingness to sign a written informed consent document

Ki nem vehet részt

  • Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment
  • Any prior radiotherapy to the lung
  • Any prior treatment for NSCLC
  • Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
  • Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg
  • Any history of a severe hypersensitivity reaction to any monoclonal antibody
  • Any history of allergy to the study drug components
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study
  • Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications
  • previous malignancies
  • history of interstitial lung disease
  • Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy
  • Active systemic infection requiring therapy
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • primary tumors involving the esophagus
  • pancoast tumors
  • Patients cannot have primary tumors which would remain unresectable
  • Patients requiring continuous supplemental oxygen
  • Pregnant or lactating women

Helyszínek itt: Egyesült Államok

  • University of KentuckyLexington, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.

A vizsgálat 2 csoportja

  • Combination Chemotherapy and Nivolumab and SurgeryA vizsgált kezelés

    Patients with lung cancer receiving combination therapy with surgery

    Kezelés: Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery és Post Induction XRT

  • Combination Chemotherapy and Nivolumab and RadiationA vizsgált kezelés

    Patients with lung cancer receiving combination therapy with radiation

    Kezelés: Nivolumab and Chemotherapy, Nivolumab és Post Induction XRT

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)
A regiszteradat frissítve
2025. április 30.